Had a great time presenting at the AI for Oncology workshop in the beautiful island of Spetses ☀️☀️. Really thankful to the co-chairs arsela prelaj and Helena Linardou for the invitation!

Out now in JTO & JTO CRR consensus recommendations from IASLC on use of neoadjuvant and adjuvant therapy for lung cancer. #lcsm jto.org/article/S1556-…

Priviliged to have spent 4 days with friends and colleagues from all over the 🌎in the beautiful historic setting of AKSS Spetses for the first “Workshop on AI in Oncology: applications & challenges”. We interacted and learned from AI experts, delved into the exciting new world

Stop pembro after 2 years? In 43,359 pts that received up-front pembrolizumab for an advanced NSCLC, continuation beyond 2 years was not associated with better OS than a fixed 2-year treatment, HR = 0.97 [0.75–1.26] p = 0.95. Adrien Rousseau sciencedirect.com/science/articl…

Can we predict risk of immune related toxicity with immunotherapy for NSCLC? Report Clinical Lung Cancer showed 15.2% rate of high-grade irAEs overall (esp respiratory and GI) with higher risk seen with mutations in MYC, TEK, FANCA, FAM123B, MET. clinical-lung-cancer.com/article/S1525-…

Curious to learn about the evolution of #I3LUNG from each of our partners' perspectives? Watch the videos here: 🇪🇺 Legal partner A. Halid Kayhan: i3lung.eu/about-us/ku-le… 🇪🇺 Clinical partner Ramon Amat: i3lung.eu/about-us/vhio/

Greek 🇬🇷 “Mythology” Part 2: It was a great honour and a huge pleasure to discuss advances in Precision oncology in #NSCLC with the liquid biopsy “queen” Elsa Anagnostou and the #KRAS “king” Ferdinandos Skoulidis , so proud of you! A fascinating discussion for all Greek-speaking oncologists

💡How to choose among second line treatment options after chemo-immunotherapy failure in advanced #NSCLC? Hope you find this short video recorded during #ASCO24 useful #some #lcsm VJ Oncology OncoAlert Oncology Brothers ΕΟΠΕ Published by VJ Oncology vjoncology.com/video/hh-u3xl4…

Half of people with inherited BRCA1/2 mutations are men, yet very few men are offered genetic testing or know the importance to their own health. Article reviews data & screening recommendations aimed to help men take action to reduce their risk of cancer. ja.ma/3WG4Nds

Steroids for irAEs & ICI efficacy: patient-level analysis from 6 trials Journal of Clinical Oncology: - 1959pts (CM-067, -142, -214,-648, -743,) - 834 had immunosuppression for irAEs - higher peak steroid dose assoc w ⬇️PFS, ⬇️OS, cumulative dose was not OncoAlert #LCSM ascopubs.org/doi/10.1200/JC…

At the #ESMO24, the ESMO Women for Oncology Committee will present new findings on female representation in leadership positions. Read the interview with Helena Linardou on the #ESMODailyReporter discussing the status of #GenderEquity in oncology ow.ly/cBPO50Tfeeb

Great start today for the educational part of #WCLC24 with a constructive debate on the optimal duration of #IO based on real cases. Mindful and provocative discussion by the two amazing ladies Heather Wakelee and Lecia Sequist, MD, MPH . Conclusion: Not a Marathon, not a sprint, but a

Presidential Symposium No1 in #WCLC24 kicks off , with Harmoni-2, a Rand Ph3 trial of Ivonescimab, a bi-specific Ab against PD1 and VEGF , compared to Pembro in pts with PDL1+ NSCLC: ➡️ mPFS benefit striking!!= 11.14 vs 5.82m , HR=0.51 ➡️ PFS HR=0.46 in PDL1>50% ➡️non-SQ

#WCLC24 Indirect patient-level comparison of neoadjuvant Nivo ( Checkmate 816 ) vs perioperative Nivo ( CM-77T) by Patrick Forde : ➡️ 40% reduction in the risk of recurrence or death with peri- as compared to neoadj ➡️ Magnitude of benefit greater in PDL1<1%, in st3 vs st2

Dr. Marina Garassino at #WCLC24 Presidential Plenary presents Normalized Membrane Ratio of TROP2 as a biomarker for datopotamab deruxtecan in TROPION-Lung01 (Dato-DXd vs docetaxel in previously treated NSCLC which previously showed PFS benefit with Dato-DXd.

#WCLC24 Presidential I Patient-level analysis CM77T v CM816, exploring what adj IO adds: - propensity-matching analysis for EFS - pCR HR 0.58, nonpCR HR 0.65 - PDL1+ HR 0.86, PDL1- HR 0.51, all favor periop IO Some 95% CIs cross 1, sample sizes small. But important data IASLC

#WCLC24: Looking at the hero behind the hero: Who needs chemotherapy on the top of a TKI in oncogene-addicted NSCLC? Algorithmic dissection by Solange Peters underpinning risk factors: ➡️ ct-DNA prognostic but may also be predictive for the need for intensified treatment